This post was originally published on this site

[unable to retrieve full-text content]Novavax (NASDAQ: NVAX) stands as a clear outlier. At the beginning of 2020, the biotech’s market cap was below $130 million. Even after a remarkable share price surge so far this year, Novavax remains …